Rio2 aims for early 2026 gold pour as Chile mine build ramps up
A total of US$30.1 million has been spent so far, just a smidgen under the company's US$30.5M forecast budget to this point, with major construction milestones already checked off and a string of other developments still to come this year.
Perched high in Chile's legendary Maricunga gold belt at a lofty 4500 metres, Rio2's Fenix Gold project spans 2000 hectares and hosts 389 million tonnes of ore going at 0.38 grams per tonne (g/t) gold for a whopping 4.8 million ounces of gold in the measured and indicated category.
The company's initial plan - expected to cost US$135M (A$211M) in initial investment capital - is to produce 91,000 ounces a year at a higher grade 0.54g/t gold for 12 years. The mine is forecast to average 82,000 ounces a year at 0.48g/t gold over a 17-year life.
Underpinning the project's healthy economics, the all-in sustaining cost of extracting the gold is forecast to run at a cheap US$1250 per ounce, thanks to an ultra-low 0.85:1 stripping ratio.
In a departure from traditional large mining projects, Rio2 is building a run-of-mine heap leach operation at Fenix Gold to process the ore.
Heap leaching is a system of piling ore on a thick polyethylene pad and spraying it with a chemical solution to dissolve and extract the gold. Since the need for crushing and a tailings dam is eliminated, the mine's footprint and environmental load should be dramatically reduced.
The company's focus in the past five months has zeroed in on critical path infrastructure, including upgrades to access its roads and the installation of a pregnant leach solution pond.
The 10ha leach pad is due to be finished next month, complete with over- liner materials.
An adsorption-desorption-recovery plant is already well underway and is set to be sealed and winter-ready shortly. Rio2 has pencilled in plant commissioning for November.
Management says all long-lead procurement items have either been acquired and placed in storage or locked in for delivery, smoothing the way for the project's next development phase.
A grade control drilling program has begun across the initial pit areas to cover the first three years of planned production, which is aimed at de-risking the early years of the mine plan.
Rio2's 2023 feasibility study put a conservative US$210.3m (A$333m) after-tax net present value (NPV) at a 5 per cent discount rate on its Chilean gold project, assuming a gold price of just US$1750 an ounce. This is enough to deliver a solid 3.5-year payback.
With gold now trading at close to double that price, Rio2's upside looks massive. Rio2's modelling shows the NPV will blast to US$546M (A$854M) at a gold price of US$2250, with the project throwing off a stunning 64 per cent internal rate of return.
Rio2 is also running a ruler over a phase two expansion plan that could turbocharge output to 250,000–300,000 ounces of gold a year by lifting daily processing rates at the project from 20,000t to 80,000t. The study is slated for a December reveal.
The site is now a hive of activity with 1240 personnel - including contractors - employed on construction works. Rio2 says it has taken particular care to focus on recruiting a local workforce, 94 per cent of whom are Chilean with 41 per cent hailing from the local Atacama region. Eleven per cent of the site's team is female, which is in line with ESG standards for gender diversity in mining.
With boots on the ground and strict standards in place, the company's commitment to safe, responsible development appears clear. Fenix Gold has so far logged more than 657,000 hours with only one lost time incident coming from a finger injury - resulting in a lost time incident frequency rate of 1.52.
For a junior such as Rio2, Fenix Gold is an ambitious and transformative venture. However, with timelines holding firm and milestones falling into place, the project appears to be shaping up as a flagship example of modern, responsible mining in South America.
Is your ASX-listed company doing something interesting? Contact:
matt.birney@wanews.com.au
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
West Australian
9 minutes ago
- West Australian
Lindian triples rare earths mining area at huge Malawi project
Lindian Resources can now significantly increase its rare earths mining area by almost three-fold at its Kangankunde project in Malawi after receiving departmental approval for its stage two modular expansion plan. In a further positive step forward in the company's plans to supercharge its stage-two expansion of the world-class rare earths project, Malawi's Mining and Minerals Regulatory Authority approved Lindian's application to expand its mining licence area to 2500 hectares (ha), up from 900ha. The achievement comes hot on the heels of Lindian's recent deal for a massive offtake agreement and potential cornerstone funding with critical mineral powerhouse and ASX-listed Iluka Resources, which has a current market value of more than $2.5 billion. Lindian management says the expanded mining footprint will bolster a targeted stage one production output of 15,300 dry metric tonnes per annum (tpa) of monazite concentrate up to a possible 75,000tpa to 100,000tpa. It cautions the potentially massive jump in output is not a forecast or production target, but is based on the huge increase in mineable land it can sink its mining teeth into. The globally significant Kangankunde rare earths project has a JORC-compliant 261-million-tonne mineral resource and an initial life-of-mine of 45 years. Expansion of the mining licence area provides Lindian with the regulatory backing to explore the options to substantially boost its production capacity by scaling up operations and developing critical project infrastructure. The company plans to target its stage two modular expansion in parallel with the project's stage one processing plant development. The Iluka agreement, announced last week, will see the critical mineral stalwart chip in a US$20 million (A$30.6 million) construction loan, accompanied by a 15-year offtake deal for 6000tpa, or a total of 90,000t of Kangankunde's premium monazite concentrate. The super high-grade deposit will produce a premium rare-earth concentrate that rocks the scales at 55 per cent total rare earth oxides (TREO), with near-20 per cent of total oxides consisting of the valuable magnet rare earths of neodymium and praseodymium, which are critical for use in renewable energy applications and electric vehicle motors. Kangankunde's stage one expected production of 15,300t of monazite concentrate will pump out about 1600t of the two magnet metals over its whopping mine life of 45 years, which could grow exponentially due to the huge increase in mining area and massive resource on hand. The project comes with an anticipated pre-production capex of US$40 million and operating costs of US$2.92 per kilogram of rare earth oxides, leading management to believe the project hovers in the much-coveted lowest cost quartile globally. Lindian's agreement with Iluka appears to be perfect timing for the duo, with Iluka chasing feed for its under-development Eneabba rare earths refinery in Western Australia's Mid West region. The commission process at Australia's first government-backed rare earths facility is expected to kick off in 2027. With talk of the Albanese-led Labor Government considering the introduction of a magnet rare earths price floor mechanism, possibly in line with United States President Donald Trump's much-heralded support for the US rare earths industry, Iluka could be in the box seat to pump as much material as possible into the new refinery. Iluka also has a right of first refusal for additional long-term offtake material from Kangankunde of up to 25,000tpa for 15 years, subject to Iluka providing a 50 per cent debt funding offer for the stage two capital cost expansion. The Kangankunde project is gaining momentum with positive news aplenty in recent months and may receive a further boost to its Iluka tie-in, if the Federal Government comes to the party with a rare earths pricing deal. Is your ASX-listed company doing something interesting? Contact:
News.com.au
9 minutes ago
- News.com.au
Steve Allen never won in 214 PGA Tour starts but has three wins on Champions Tour in 2025
More than 20 years after his crowning achievement, winning the Australian Open, financial need turned Steve Allen to the Champions Tour in the US. Now three wins later and with more than $3m in prizemoney, things are no longer a' little bit tight' for the 51-year Victorian, who has tasted victory again. Allen, the 2002 Australian Open champ who never won on the US PGA Tour, took down a field including major champions Ernie Els and Darren Clarke to record a one-shot win over 2009 British Open winner Stewart Cink at the Boeing Classic. It's a remarkable turn of events for Allen, who had to go through qualifying school to get on the Champions Tour and has racked up $3.1m in prizemoney across 2024 and 2025, with $2m coming on the back of his three wins this year. Allen found it hard to explain his late-career success but said not worrying about money now helped a bit. 'Yes, definitely, definitely less stress, I think. You know, coming through Q-School to get on this tour and having a chance at 50 to play golf for money is amazing, so it's all bonus,' he said. 'I've been off the main tour since 2009, so things get a little bit tight there when you're not making any money. I think with that, matured a bit, not getting ahead of myself, not stressing about things and just playing and seeing what happens. 'Like I said, I'm not trying to force it. I'm not getting upset when things go wrong, I'm just trying to play and have fun. 'I think I found a bit of a groove with my swing. I think I'm more aware of what I'm doing wrong when it goes wrong. I had a fairly tough few years there, so when things do start to go wrong there, I'm not panicking anymore. "There's a lot of jackets in golf. It's nice to have one." @SAllan66 gets to add to his wardrobe thanks to the trophy @BoeingClassic 😂 — PGA TOUR Champions (@ChampionsTour) August 11, 2025 'Beginning of last year I had a few tournaments where I didn't play very well, so I'm going into today, just let it happen. I'm not trying to force it, I'm not trying to push it, I'm just trying to play.' Allan played 214 US PGA Tour events and 164 more on the US secondary tour without a win before turning into a trophy hunter after turning 50, the qualification age to play on the Champions Tour.
News.com.au
3 hours ago
- News.com.au
Health Check: Syntara shares plunge on FDA ‘do more trial homework' edict
Syntara shares tumble almost 50% after the FDA 'suggests' another trial Avita Medical looks to raise capital after a disappointing quarter EBR Systems is on track for limited US launch of its novel heart pacing device Shares in cancer drug developer Syntara (ASX:SNT) this morning lost almost half their value, after unfavourable advice from the US Food & Drug Administration (FDA). The agency has advised the company to do a placebo-controlled phase II trial, before proceeding with a proposed pivotal study for myelofibrosis. As any drug developer would attest, it's always a good idea to take the agency's counsel on board. The FDA wants a placebo-controlled trial to glean "additional safety and efficacy data'. Syntara says the trial should focus on improvements in symptoms and spleen volume reductions, 'in order to optimise the design and efficiency of a subsequent pivotal phase III trial'. Agency takes "conservative" approach CEO Gary Phillips today told investors the company only heard the news on Saturday and was still digesting the implications. 'The FDA has taken a more conservative approach to get the drug to approval,' he says. 'It's not the fast track we were looking for, but nonetheless their guidance is extremely helpful.' In effect, the company can't leapfrog to a planned phase II/III trial, enrolling up to 300 patients at a cost of around US$80 million. The company now is likely to carry out a 90-patient phase 2b study, probably with 60 on active treatment and 30 on placebo. Phillips estimates the cost 'in order of US$25 million', but the study would mean a subsequent phase III trial potentially could be smaller and cheaper. The FDA's stance does blow out the company's time lines, given the phase II effort would take 12 to 18 months to recruit. Ironically, the more circuitous path means lower short-term cash requirements: the company's $15 million should last into 2027, rather than mid 2026 as envisaged. 'The FDA has given us a different clinical path, but everything else around this asset remains the same,' Mr Phillips says. Promising early results The FDA mulled the interim data from Syntara's ongoing phase 1c/2 trial, which tests Syntara's amsulostat (SNT-5505) in combination with the standard-of-care ruxolitinib. Results to date from the open-label study suggest amsulostat 'may deliver deep and long-lasting benefit of patients who are sub optimally controlled by ruxolitinib alone'. Syntara values the myelofibrosis market at US$1 billion a year. Meanwhile, the company expects to release further results from the current open-label trial before the end of September. Reimbursement 'confusion' crimps Avita's sales Friday's poorer-than-expected June quarter result from Avita Medical (ASX:AVH) shows the burns and wounds care pioneer is lagging its revenue and earnings targets, with US reimbursement delays delaying sales from upgraded products. Avita has commercialised Recell for thermal burn wounds and full-thickness skin defects. Unlike other treatments, Recell harnesses the patient's own skin in a spray-on format. In May 2024 the FDA approved Recell Go, which has enhanced features for clinicians. The agency in December then approved Recell Go Mini, for smaller wounds of up to 480 square centimetres. Missing expectations In short, the US rollout has been slower than expected, partly because of reimbursement delays. Bell Potter suggests this resulted from confusion over administration of these payments, which saw physicians not getting paid. There's no Hell like a doctor not being remunerated and they reverted to alternative therapies including skin grafts. Avita posted June quarter revenue of US$18.2 million 20% higher year-on-year but flat on the March quarter tally. The numbers were around 16% below market expectations. June half revenue gained 35% to US$36.5 million. The company lost US$9.9 million in the quarter, compared with a US$15.39 deficit a year ago. Management has trimmed calendar 2025 guidance to US$76-81 million, from the previously guided US$100-106 million. The tally is 19-27% higher year on year. Balance sheet concerns As of June 30, Avita had cash and equivalents of US$15.7 million. It also has a US$40 million debt facility, from specialist lender Orbimed Advisors. The company has won a series of waivers its debt covenants, relating to minimum quarterly and annual revenue. But Avita must continue to maintain a minimum US$10 million of cash. In a 'going concern' note to the accounts, management says that 'absent any mitigating action, the company probably won't be able to comply with a minimum cash balance covenant within the next 12 months. 'The company is actively evaluating strategies to obtain the required additional funding for future operations. This includes an equity raising.' Broker Morgans says 'despite a significant shortfall in sales, Avita successfully rolled through cost-base reductions as planned, decreasing the net loss with more to come in ." Nonetheless, "another missed guidance target is unlikely to reassure investors, and it is now evident that additional capital will be necessary to support the company to profitability.' Rating the stock a 'speculative buy', Morgans forecasts a calendar 2025 loss of US$36.5 million, improving to a US$18.1 million deficit in 2026. Avita then cracks a US$5.6 million profit in 2027. Morgans assumes a US$50 million equity raising. Bell Potter believes the administrative 'confusion' resulted in a 20% drop in demand for Recell over the half – a 'material circa $5 million in lost revenues over the top 10 accounts alone'. The firm says Medicaid patients account for 70-75% of Recell volumes, 'hence it is critical that the matter is resolved without further delay'. Avita shares have tumbled close to 20% since Thursday's close and have lost about two-third of their value since the start of the year. EBR Systems readies US rollout Following a pilot stage, EBR Systems (ASX:EBR) is on track to roll out its novel heart device in the US market in the December quarter. In April the FDA approved WISE, the world's first and only leadless pacing system for heart failure. Addressing a Canaccord Genuity conference in Boston, EBR CEO John McCutcheon said the company would focus on 'strategic' hospitals. Crucially, in October EBR won reimbursement for both inpatient and outpatient settings, at up to US$63,300 per procedure. EBR cites an 'initial addressable market' in the US of US$3.6 billion. In early June EBR announced its first commercial implants, at St David's Medical Centre in Texas and the Cleveland Clinic.
